Results 91 to 100 of about 17,302 (216)
Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale.
, 2015 International audienceAzacitidine is a mainstay for treating hematological disorders. Azacitidine is metabolized by cytidine deaminase, coded by a highly polymorphic gene.J, Ciccolini, J, Colle, L, Ouafik, G, Venton, C, Serdjebi, B, Lacarelle, C, Mercier, R., Costello, F, Fina, R, Fanciullino +9 morecore +1 more sourceThe role of the adenosinergic pathway in resistance to hypomethylating agents in patients with high‐risk myelodysplastic syndromes
British Journal of Haematology, EarlyView.George Vrachiolias, Eleftheria Lamprianidou, Athanasios Tasis, Theodoros Spyropoulos, Despoina Dimitriou, Chryssa Kymparidou, Christina Misidou, Konstantinos Liapis, Emmanouil Spanoudakis, Maria Koffa, Menelaos Papoutselis, Iliana Stamatiou, Elsa Bernard, Elli Papaemmanuil, Ioannis Mitroulis, Ioannis Kotsianidis +15 morewiley +1 more sourceTreatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion
Journal of the European Academy of Dermatology and Venereology, EarlyView.Systematic review of 108 studies with a total of 182 patients with interstitial granulomatous dermatitis (IGD). IGD was frequently associated with systemic conditions or drug exposure. Management includes careful medication review and prompt withdrawal of potential triggers. Corticosteroids (systemic and topical) were commonly effective, while biologic Francesco Bellinato, Sara Salvagno, Chiara Colato, Paolo Gisondi, Giampiero Girolomoni +4 morewiley +1 more sourceCross‐Regulation Between DNA Methylation and Circadian Clock Reprogramming in Ovarian Cancer: Mechanistic Insights, Biomarker Potential, and Therapeutic Implications
International Journal of Cancer, Volume 160, Issue 1, Page 7-23, 1 January 2027.ABSTRACT
Early diagnosis remains challenging, recurrence rates remain high, and platinum resistance frequently develops in ovarian cancer (OC), collectively representing major barriers to long‐term patient survival. DNA methylation (DNAm), as a relatively stable yet dynamically modifiable epigenetic signature, can capture alterations in tumor states ...Min Xing, Chang Zhou, Yi Tang, Shuhui Xu, Shasha Zhou, Weiai Liu, Huiping Liu +6 morewiley +1 more sourcePhase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
, 2011 Purpose To determine the maximum-tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia ...Heidi Giordano, Hagop Kantarjian, Guillermo Garcia-Manero, Renee Ward, Sarah Sakoian, Eric Laille, Elias Jabbour, Steven D. Gore, Kyle J. MacBeth, Christopher Cogle, Barry Skikne, Tao Shi +11 morecore +1 more sourceEpigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies
International Journal of Cancer, Volume 159, Issue 11, Page 2633-2652, 1 December 2026.ABSTRACT
Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).Neeraj Kumari, Pablo Hoffmann, Laura Reichl, Maximilian Schmutz, Nina Fischer, Thi Tuong Vi Dang, Fulvia Ferrazzi, Pascal Johann, Michaela Kuhlen, Constantin Lapa, Rainer Claus +10 morewiley +1 more sourceAzacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children’s Oncology Group trial AALL15P1
Haematologica
Infants less than 1 year old diagnosed with KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukemia (ALL) are at high risk of remission failure, relapse, and death due to leukemia, despite intensive therapies. Infant KMT2A-r ALL blasts are characterized Erin M. Guest, John A. Kairalla, Meenakshi Devidas, Emily Hibbitts, Andrew J. Carroll, Nyla A. Heerema, Holly R. Kubaney, Margaret A. August, Sidharth Ramesh, Byunggil Yoo, Midhat S. Farooqi, Melinda G. Pauly, Daniel S. Wechsler, Rodney R. Miles, Joel M. Reid, Cynthia D. Kihei, Lia Gore, Elizabeth A. Raetz, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown +20 moredoaj +1 more sourceFrom infusion to pills in acute myeloid leukaemia: Reorganizing care beyond the infusion unit
British Journal of Haematology, EarlyView.Fortunato Morabito, Enrica Antonia Martino, Antonella Bruzzese, Nicola Amodio, Santino Caserta, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Ernesto Vigna, Massimo Gentile +11 morewiley +1 more sourceIdentification of a Novel KRAS::ETNK1 Fusion Transcript in a Myelodysplastic/Myeloproliferative Overlap Syndrome With Eosinophilia: A Case Report
eJHaem, Volume 7, Issue 6, December 2026.ABSTRACT
This work describes, to our knowledge, the first reported case of a patient with an MDS/MPN overlap syndrome harboring a novel KRAS::ETNK1 fusion transcript. The disease initially presented with eosinophilia, megakaryocyte expansion, mast cell infiltration, and a background of typical MDS/MPN‐associated mutations (ASXL1, TET2, EZH2, BCOR, and ...Marianne Caledec, Hélène Labussière‐Wallet, Juliette Fontaine, Marie Larcher, Fiorenza Barraco, Marie Balsat, Anne‐Marie Daull, Zofia Gross, Juliette Helluin, Sandrine Loron, Lila Gilis, Sophie Ducastelle‐Lepretre, Gaelle Fossard, Mael Heiblig, Pierre Sujobert, Morgane Fontaine, Sandrine Hayette, Vincent Alcazer +17 morewiley +1 more sourceLong-term follow-up of VIALE-A : Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia
Venetoclax-azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall survival (OS) analysis of the VIALE-A study (NCT02993523).Porkka, Kimmo, Garcia, Jacqueline S, Leber, Brian, Miller, Catherine, Garcia, Jacqueline S., Illés, Árpád, Döhner, Hartmut, Pratz, Keith W, Pullarkat, Vinod, Yeh, Su Peng, Potluri, Jalaja, Récher, Christian, Yamamoto, Kazuhito, Yoon, Sung Soo, Chyla, Brenda, Ku, Grace, DiNardo, Courtney D, Esteve, Jordi, Fiedler, Walter, Thirman, Michael J, Wolach, Ofir, Zhou, Ying, Turgut, Mehmet, Yeh, Su-Peng, Jonas, Brian A, Jonas, Brian A., DiNardo, Courtney D., Mayer, Jiri, Lemoli, Roberto M, Thirman, Michael J., Wang, Jianxiang, Lemoli, Roberto M., Zhang, Meng, Pratz, Keith W., Yoon, Sung-Soo +34 morecore +1 more source